By Ben Glickman

Bausch Health Cos. has received approval from the Food and Drug Administration for Cabtreo, its topical gel for acne.

The Laval, Quebec-based pharmaceutical company said the treatment, which combines clindamycin phosphate, adapalene and benzoyl peroxide, is expected to become available in the first quarter of 2024.

The approved new drug application allows for the use of Cabtreo in treating acne vulgaris in patients 12 years and older.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

October 20, 2023 17:50 ET (21:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Bausch Health Companies (TSX:BHC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024 Plus de graphiques de la Bourse Bausch Health Companies
Bausch Health Companies (TSX:BHC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024 Plus de graphiques de la Bourse Bausch Health Companies